Our research in heart failure and transplantation includes:
- Gene therapy. In the CUPID trial (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease), Roger Hajjar, MD, Professor of Cardiology and Director of Cardiovascular Research, and Jill Kalman, MD, Associate Professor of Cardiology and Director of the Cardiomyopathy Program at Mount Sinai Heart, have developed a new gene therapy, now in initial trials, that is safe and effective in reversing advanced heart failure.
- Stem cell research. Mount Sinai researchers have developed stem cells, — immature cells that have the potential to develop into specialized cell types — that mimic diseased heart cells. This may allow scientists to develop drug therapies to stop the disease from occurring or progressing.
- Replacement cells. The gene cyclin A2, which controls cell division, shuts down in the heart not long after birth and remains dormant thereafter. Hina Chaudhry, MD, Director of Cardiovascular Regenerative Medicine and Senior Faculty of Cardiology, is investigating ways to keep this gene turned on , which would for the first time allow new heart cells to take the place of those damaged and destroyed.